Risperidone

Category: pharmaceutical · Atypical antipsychotic
Record: specific compound · in current use
Identifiers: CAS 106266-06-2
Aliases: —

Atypical antipsychotic with a strong prolactin effect. Metabolic disruption is recorded as weaker than olanzapine in this seed.

Flags: pharmaceutical

Phase-1 numbers are seed hypotheses. They are not curated consensus, not a toxicity total, and not a statement of human risk. Association is not written as causation.

Hyperprolactinemia +4 · H4 · high

Hyperprolactinemia is an established pharmacological outcome. It is not an insulin-resistance outcome.

Phase-1 seed hypothesis, not a curated systematic review. Where a range was discussed, the stored integer is the conservative end closer to zero. A score is biological direction and magnitude, not human risk.